Payment overview · 2025
General Payments
$811.25
18 reported records · 6 companies
Healthcare provider profile · identity verified
Alberto E Almeida, M.D,
Allopathic & Osteopathic Physicians|Family Medicine · BROWNSVILLE, TX · NPI 1114988516
Verified facts
What the public records show
CMS Open Payments records show Alberto E Almeida, M.D, received $811.25 in general payments during 2025 across 18 reported records.
Lilly USA, LLC accounted for 66.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $536.79 | 66.2% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.54 | 18.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.85 | 4.5% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $30.32 | 3.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $28.09 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.66 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $811.25 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $513.21 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.36 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.66 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.54 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $10.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 128 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 120 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
128 | 55 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
120 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
144 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 900 | 306 |
| Metformin Hcl | Metformin Hcl | 765 | 255 |
| Lisinopril | Lisinopril | 494 | 148 |
| Amlodipine Besylate | Amlodipine Besylate | 491 | 156 |
| Losartan Potassium | Losartan Potassium | 410 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 97 |
| Simvastatin | Simvastatin | 206 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 199 | 78 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 55 |
| Donepezil Hcl | Donepezil Hcl | 170 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 68 |
| Gabapentin | Gabapentin | 165 | 69 |
| Glipizide | Glipizide | 158 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 151 | 55 |
| Rybelsus | Semaglutide | 144 | 34 |
| Carvedilol | Carvedilol | 134 | 46 |
| Farxiga | Dapagliflozin Propanediol | 128 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 71 |
| Trazodone Hcl | Trazodone Hcl | 124 | 45 |
| Mounjaro | Tirzepatide | 120 | 14 |
| Omeprazole | Omeprazole | 118 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 114 | 49 |
| Azithromycin | Azithromycin | 111 | 93 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 104 | 53 |
| Famotidine | Famotidine | 97 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 94 | 39 |
| Furosemide | Furosemide | 94 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 93 | 33 |
| Ozempic | Semaglutide | 92 | 23 |
| Meclizine Hcl | Meclizine Hcl | 87 | 42 |
| Sertraline Hcl | Sertraline Hcl | 83 | 34 |
| Alendronate Sodium | Alendronate Sodium | 72 | 27 |
| Eliquis | Apixaban | 72 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 71 | 20 |
| Meloxicam | Meloxicam | 70 | 50 |
| Alprazolam | Alprazolam | 68 | 15 |
| Memantine Hcl | Memantine Hcl | 66 | 25 |
| Baclofen | Baclofen | 65 | 49 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 55 |
| Montelukast Sodium | Montelukast Sodium | 62 | 27 |
| Buspirone Hcl | Buspirone Hcl | 61 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 23 |
| Clotrimazole | Clotrimazole | 58 | 27 |
| Ibuprofen | Ibuprofen | 56 | 34 |
| Enalapril Maleate | Enalapril Maleate | 54 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 38 |
| Jardiance | Empagliflozin | 52 | 22 |
| Allopurinol | Allopurinol | 51 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 25 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 47 | 19 |
| Naproxen | Naproxen | 47 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 42 | 16 |
| Glipizide Er | Glipizide | 41 | 15 |
| Propranolol Hcl | Propranolol Hcl | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 31 |
| Vascepa | Icosapent Ethyl | 39 | 17 |
| Ketoconazole | Ketoconazole | 37 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 17 |
| Levemir Flexpen | Insulin Detemir | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 28 |
| Januvia | Sitagliptin Phosphate | 34 | 11 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Atenolol | Atenolol | 31 | 12 |
| Potassium Chloride | Potassium Chloride | 31 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | 11 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Mupirocin | Mupirocin | 27 | 20 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Terbinafine Hcl | Terbinafine Hcl | 26 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ciclopirox | Ciclopirox | 25 | 14 |
| Telmisartan | Telmisartan | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 24 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | 11 |
| Nystatin | Nystatin | 24 | 14 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 15 |
| Torsemide | Torsemide | 20 | suppressed |
| Clarithromycin | Clarithromycin | 19 | 19 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | 11 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Kerendia | Finerenone | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $811.25 · 18 records | Lilly USA, LLC | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, JARDIANCE, MOUNJARO, Ohtuvayre, Ozempic, Rybelsus, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error